Raymond James analyst Jayson Bedford raised the firm’s price target on Boston Scientific to $54 from $48 and keeps a Strong Buy rating on the shares. Boston Scientific has rebounded well off a choppy 2H19/2021 and has emerged as one of the more balanced, and consistent growers in the sector, Bedford tells investors in a research note. The analyst sees sources of margin expansion, which should drive ~11% EPS growth in 2023/2024.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on BSX:
- Wolfe Research cuts Edwards Lifesciences to Peer Perform on macro, TAVR maturity
- Apollo Endosurgery downgraded to Hold from Buy at Lake Street
- Piper says Apollo Endosurgery can help Boston Scientific expand ELS franchise
- Craig-Hallum sees potential for competing Apollo Endosurgery bids
- Boston Scientific to Acquire APEN For $10 Per Share
